L1CAM and glioma: Twelve studies investigated the effects of the cleaved, soluble N-terminal ectodomain of L1CAM (L1CAM-ECD) on tumor progression, mostly focusing on gliomas, ovarian cancer, and pancreatic cancer [16,33,34,40,41,44,67,74,75,76,77,78].